MX369357B - Procedimiento de compuesto antifungico. - Google Patents

Procedimiento de compuesto antifungico.

Info

Publication number
MX369357B
MX369357B MX2016012053A MX2016012053A MX369357B MX 369357 B MX369357 B MX 369357B MX 2016012053 A MX2016012053 A MX 2016012053A MX 2016012053 A MX2016012053 A MX 2016012053A MX 369357 B MX369357 B MX 369357B
Authority
MX
Mexico
Prior art keywords
antifungal compound
compound process
preparing compound
useful
antifungal
Prior art date
Application number
MX2016012053A
Other languages
English (en)
Other versions
MX2016012053A (es
Inventor
J Hoekstra William
m yates Christopher
Behnke Mark
Alimardanov Asaf
A David Scott
Franklin FRY Douglas
Original Assignee
Mycovia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mycovia Pharmaceuticals Inc filed Critical Mycovia Pharmaceuticals Inc
Publication of MX2016012053A publication Critical patent/MX2016012053A/es
Publication of MX369357B publication Critical patent/MX369357B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Artificial Filaments (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se refiere a un procedimiento para preparar el compuesto 1 que es útil como un agente antifúngico. En particular, la invención busca proporcionar una nueva metodología para preparar el compuesto 1 y derivados substituidos del mismo.
MX2016012053A 2014-03-19 2015-03-19 Procedimiento de compuesto antifungico. MX369357B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461955532P 2014-03-19 2014-03-19
PCT/US2015/021464 WO2015143154A1 (en) 2014-03-19 2015-03-19 Antifungal compound process

Publications (2)

Publication Number Publication Date
MX2016012053A MX2016012053A (es) 2017-04-27
MX369357B true MX369357B (es) 2019-11-06

Family

ID=54145313

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012053A MX369357B (es) 2014-03-19 2015-03-19 Procedimiento de compuesto antifungico.

Country Status (12)

Country Link
US (2) US10077250B2 (es)
EP (1) EP3119771B1 (es)
JP (1) JP6606508B2 (es)
KR (1) KR20160138013A (es)
CN (1) CN106459022B (es)
AU (1) AU2015231208B2 (es)
BR (1) BR112016021282A8 (es)
CA (1) CA2942930A1 (es)
EA (1) EA201691648A1 (es)
ES (1) ES2800905T3 (es)
MX (1) MX369357B (es)
WO (1) WO2015143154A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2815373T3 (es) 2014-03-19 2021-03-29 Mycovia Pharmaceuticals Inc Procedimiento de compuesto antifúngico
CA2942936A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
CA2942932A1 (en) * 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
EA201691648A1 (ru) 2014-03-19 2017-01-30 Ваймет Фармасьютикалс, Инк. Способ получения противогрибковых соединений
MX371291B (es) 2014-03-19 2020-01-24 Viamet Pharmaceuticals Nc Inc 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)- 3-(1h-tetrazol-1-il)propan-2-oles y procedimientos para su preparacion.
JP2017509646A (ja) * 2014-03-19 2017-04-06 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 抗真菌化合物の調製方法
CA2942231A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
MX382905B (es) * 2014-03-19 2025-03-13 Viamet Pharmaceuticals Nc Inc 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)-3-(1h-tetrazol-1-il)propan-2-oles y procesos para su preparacion.
US10196375B2 (en) 2014-03-19 2019-02-05 Mycovia Pharmaceuticals, Inc. Antifungal compound process
HUE053638T2 (hu) 2015-09-18 2021-07-28 Mycovia Pharmaceuticals Inc Eljárás gombaellenes vegyület elõállítására
WO2019092086A1 (en) 2017-11-13 2019-05-16 Bayer Aktiengesellschaft Tetrazolylpropyl derivatives and their use as fungicides
CN114573557B (zh) * 2022-03-28 2024-03-08 浙江天宇药业股份有限公司 一种奥特康唑的制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2854015B2 (de) 1978-12-14 1980-10-09 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur Herstellung von !H-TetrazoI-1-essigsauren und bestimmter Ester derselben
JP2000344744A (ja) 1999-06-04 2000-12-12 Ss Pharmaceut Co Ltd アセトフェノン誘導体およびその製法
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
KR100889937B1 (ko) 2007-08-06 2009-03-20 한미약품 주식회사 보리코나졸의 제조방법
KR101109215B1 (ko) 2009-06-17 2012-01-30 보령제약 주식회사 보리코나졸의 신규 중간체 및 이를 이용한 보리코나졸의 제조방법
US20120088664A1 (en) 2009-06-18 2012-04-12 Basf Se Antifungal 1,2,4-triazolyl derivatives having a 5-sulfur subtituent
SI2563771T1 (sl) * 2010-04-24 2016-05-31 Viamet Pharmaceuticals, Inc. Spojine inhibitorjev metaloencimov
US8901121B2 (en) 2011-06-19 2014-12-02 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
BR122020013521B1 (pt) 2011-06-19 2021-05-25 Viamet Pharmaceuticals (NC), Inc compostos inibidores de metaloenzima
JP6223329B2 (ja) 2011-06-23 2017-11-01 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 金属酵素化合物
EP2788343B1 (en) 2011-12-11 2018-02-28 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
CA2861341A1 (en) * 2012-01-20 2013-07-25 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds against fungal infection induced plant diseases and method of use thereof
JP6189865B2 (ja) 2012-01-20 2017-08-30 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 金属酵素阻害薬化合物
EP2894981B1 (en) 2012-09-12 2019-12-04 Dow AgroSciences LLC Metalloenzyme inhibitor compounds
WO2014117090A1 (en) 2013-01-28 2014-07-31 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2014165861A1 (en) 2013-04-05 2014-10-09 The Regents Of The University Of California Metal-catalyzed coupling of aryl and vinyl halides with alpha, alpha-difluorocarbonyl compounds
JP6387401B2 (ja) 2013-05-28 2018-09-05 ヴィアメット ファーマスーティカルズ（エヌシー），インコーポレイテッド 殺真菌組成物
EA201690007A1 (ru) 2013-06-12 2016-04-29 Ваймет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
EA201691648A1 (ru) 2014-03-19 2017-01-30 Ваймет Фармасьютикалс, Инк. Способ получения противогрибковых соединений
CA2942932A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
CA2942231A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
CA2942936A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
JP2017509646A (ja) 2014-03-19 2017-04-06 ヴィアメット ファーマスーティカルズ，インコーポレイテッド 抗真菌化合物の調製方法
AU2015231270B2 (en) 2014-03-19 2019-03-07 Viamet Pharmaceuticals (NC), Inc. Antifungal compound process
MX382905B (es) 2014-03-19 2025-03-13 Viamet Pharmaceuticals Nc Inc 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)-3-(1h-tetrazol-1-il)propan-2-oles y procesos para su preparacion.
ES2815373T3 (es) 2014-03-19 2021-03-29 Mycovia Pharmaceuticals Inc Procedimiento de compuesto antifúngico
MX371291B (es) 2014-03-19 2020-01-24 Viamet Pharmaceuticals Nc Inc 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)- 3-(1h-tetrazol-1-il)propan-2-oles y procedimientos para su preparacion.
US10196375B2 (en) 2014-03-19 2019-02-05 Mycovia Pharmaceuticals, Inc. Antifungal compound process
SI3271347T1 (sl) 2015-03-19 2022-11-30 Mycovia Pharmaceuticals, Inc. Protiglivične spojine in postopki za izdelavo
UA120784C2 (uk) 2015-05-18 2020-02-10 Ваймет Фармасьютікалс (Нк), Інк. Протигрибкові сполуки
HUE053638T2 (hu) 2015-09-18 2021-07-28 Mycovia Pharmaceuticals Inc Eljárás gombaellenes vegyület elõállítására
CN108882708A (zh) 2015-11-17 2018-11-23 美国陶氏益农公司 4-((6-(2-(2,4-二氟苯基)-1,1-二氟-2-羟基-3-(1h-1,2,4-三唑-1-基)丙基)吡啶-3-基)氧基)苄腈以及制备方法
CN108882709A (zh) 2015-11-17 2018-11-23 美国陶氏益农公司 4-((6-(2-(2,4-二氟苯基)-1,1-二氟-2-氧代乙基)吡啶-3-基)氧基)苄腈以及制备方法
WO2017087643A1 (en) 2015-11-17 2017-05-26 Viamet Pharmaceuticals, Inc. 4-((6-2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation
TWI637948B (zh) 2015-11-17 2018-10-11 維愛美製藥公司 製備４－（（６－（２－（２，４－二氟苯基）－１，１－二氟－２－羥基－３－（１ｈ－１，２，４－三唑－１－基）丙基）吡啶－３－基）氧基）苄腈之方法
JP6803923B2 (ja) 2015-12-30 2020-12-23 エヌキューピー １５９８，リミテッド 金属酵素阻害化合物

Also Published As

Publication number Publication date
US20190177298A1 (en) 2019-06-13
EA201691648A1 (ru) 2017-01-30
CN106459022B (zh) 2019-08-02
CA2942930A1 (en) 2015-09-24
US10077250B2 (en) 2018-09-18
BR112016021282A2 (es) 2017-08-15
AU2015231208A1 (en) 2016-10-06
US20170144990A1 (en) 2017-05-25
AU2015231208B2 (en) 2019-04-04
EP3119771A1 (en) 2017-01-25
JP2017507993A (ja) 2017-03-23
BR112016021282A8 (pt) 2021-07-20
MX2016012053A (es) 2017-04-27
KR20160138013A (ko) 2016-12-02
EP3119771B1 (en) 2020-05-06
JP6606508B2 (ja) 2019-11-13
ES2800905T3 (es) 2021-01-05
EP3119771A4 (en) 2017-11-22
WO2015143154A1 (en) 2015-09-24
CN106459022A (zh) 2017-02-22

Similar Documents

Publication Publication Date Title
MX365494B (es) Procedimiento de compuesto antifungico.
MX2016012053A (es) Procedimiento de compuesto antifungico.
MX391538B (es) Proceso de compuesto antifungico.
GB201512314D0 (en) Use of a composition containing 1,3-propanediol as an e-liquid
MX2016016143A (es) Compuestos de [1,2,4]triazol sustituido.
PH12017500833A1 (en) Synthesis of copanlisib and its dihydrochloride salt
GEAP202014494A (en) Substituted 2,4 diamino-quinoline as new anticancer agents
JO3487B1 (ar) تخليق كوبانليسيب وملح الدايهيدروكلوريد الخاص به
PH12016501865A1 (en) Pyridine-2-amides useful as cb2 agonists
PH12016501252A1 (en) Novel tetrahydropyridopyrimidine compound or salt thereof
IN2014MU00455A (es)
MX2016009117A (es) Pigmentos a base de compuestos de bismuto.
EP3119899A4 (en) Compositions and methods for producing chemicals and derivatives thereof
MX2017002015A (es) Ligando del receptor 2 de canabinoide radiomarcado.
MX2017003550A (es) Uso de cisteamina en tratamiento de infecciones causadas por levaduras/mohos.
IN2014CH00151A (es)
MX2021000508A (es) Extracto de sabadilla seco y fluido.
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона
GB201707234D0 (en) Composition & Process
UA97937U (uk) Матеріал для інтерференційних покриттів
GB201607927D0 (en) Composition & process
GB201510891D0 (en) Products, uses & methods (7)
GB201509366D0 (en) Products, uses & methods (6)
GB201507775D0 (en) Products, uses & methods (3)
GB201507774D0 (en) Products, uses & methods (2)

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: GIESECKE+DEVRIENT MOBILE SECURITY AMERICA, INC.

FG Grant or registration
HC Change of company name or juridical status

Owner name: GIESECKE+DEVRIENT MOBILE SECURITY AMERICA, INC.